Cipla Q1 Review - Covid-19, Operational Efficiency Drives Earnings: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cipla Ltd. delivered better-than-expected Q1 FY22 earnings, led by a superior product mix, operational cost efficiency, a healthy off-take of Covid-19 related products, and one-time income from the active pharma ingredient segment.
Cipla is poised to outperform the domestic formulation market and is progressing well on building a complex product pipeline for North America.
We raise our earnings per share estimate by 6%/4% for FY22E/FY23E, factoring in-
strong traction in prescription, trade generics in the domestic formulation segment,
an extended benefit from cost savings, and
lower research and development spend.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.